213 related articles for article (PubMed ID: 16970254)
21. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
Suwan N
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
[TBL] [Abstract][Full Text] [Related]
22. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
23. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
24. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
25. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
Hwang JC; Chen CA; Wang CT; Chen HC
Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144
[TBL] [Abstract][Full Text] [Related]
26. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
Bratisl Lek Listy; 2004; 105(10-11):368-73. PubMed ID: 15658577
[TBL] [Abstract][Full Text] [Related]
27. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
Shuja SB; Raja RM
Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
[TBL] [Abstract][Full Text] [Related]
28. Resting energy expenditure and its determinants in hemodialysis patients.
Kamimura MA; Draibe SA; Avesani CM; Canziani ME; Colugnati FA; Cuppari L
Eur J Clin Nutr; 2007 Mar; 61(3):362-7. PubMed ID: 16943847
[TBL] [Abstract][Full Text] [Related]
29. Risk factors of hyperparathyroidism in advanced stages of chronic kidney disease.
El Kossi M; Rana A; El Nahas M
Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):623-7. PubMed ID: 19587504
[TBL] [Abstract][Full Text] [Related]
30. Post-parathyroidectomy serum phosphate kinetics is peculiar to female hemodialysis patients with a high body mass index.
Lomonte C; Vernaglione L; Cazzato F; Casucci F; Chimienti D; Bruno A; Cocola S; Basile C
J Nephrol; 2006; 19(1):70-6. PubMed ID: 16523429
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
32. Assessment of immune status in relation to vitamin D levels in children on regular hemodialysis.
Youssef DM; Elshal AS; Abo Elazem AA
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):267-73. PubMed ID: 22382217
[TBL] [Abstract][Full Text] [Related]
33. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
[TBL] [Abstract][Full Text] [Related]
34. Significance of serum magnesium as an independent correlative factor on the parathyroid hormone level in uremic patients.
Ohya M; Negi S; Sakaguchi T; Koiwa F; Ando R; Komatsu Y; Shinoda T; Inaguma D; Joki N; Yamaka T; Ikeda M; Shigematsu T
J Clin Endocrinol Metab; 2014 Oct; 99(10):3873-8. PubMed ID: 24937533
[TBL] [Abstract][Full Text] [Related]
35. Correlation of serum parathormone with hypertension in chronic renal failure patients treated with hemodialysis.
Baradaran A; Nasri H
Saudi J Kidney Dis Transpl; 2005; 16(3):288-92. PubMed ID: 17642794
[TBL] [Abstract][Full Text] [Related]
36. Secondary hyperparathyroidism in patients on maintenance hemodialysis.
Hida M
Tokai J Exp Clin Med; 1982 Nov; 7(6):665-70. PubMed ID: 7184198
[TBL] [Abstract][Full Text] [Related]
37. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
38. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.
Kiss Z; Ambrus C; Almasi C; Berta K; Deak G; Horonyi P; Kiss I; Lakatos P; Marton A; Molnar MZ; Nemeth Z; Szabo A; Mucsi I
Nephron Clin Pract; 2011; 117(4):c373-8. PubMed ID: 21071961
[TBL] [Abstract][Full Text] [Related]
39. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
Navarro JF; Mora C; Macia M; Garcia J
Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
[TBL] [Abstract][Full Text] [Related]
40. [Parathormone and vitamin d3-metabolites in healthy children and children with chronic renal failure before and after kidney transplantation].
Pistor K; Reinhardt D; Grosse-Hohmann E; Keck E
Monatsschr Kinderheilkd; 1982 Sep; 130(9):714-20. PubMed ID: 6755227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
